Industry News

TRACON Pharmaceuticals, a clinical stage biopharmaceutical company focused on the development and commercialization of novel targeted therapeutics for cancer, wet age? related macular degeneration and fibrotic diseases, today announced a strategic licensing collaboration with Janssen..."/>
TRACON Pharmaceuticals Announces a Strategic Licensing Collaboration for Two Janssen Oncology Assets and a $5 Million Equity Investment from Johnson & Johnson Innovation – JJDC, Inc.
Image Protect Inc. announced today it has executed exclusive contracts with six of the top photo producers in the world. This brings the total number of images to be monitored for copyright protection to 50 MM, up from 1 MM in 2015. By leveraging over 30 years of professional experience in the photo industry, Image Protect has tapped into the market for monetizing millions of copyright violations worldwide."/>
Image Protect Inc. Executes Significant Industry Contracts in 2016
GenVec, Inc., a clinical-stage gene delivery company, announced that Douglas E. Brough, Ph.D., the company's chief scientific officer, will present " Exploring the AdenoVerse™ Platform for New Advanced Cell and Gene Therapies", a brief review of GenVec's technology platform, at the 2016 Cell& Gene Meeting on the Mesa. This presentation will highlight new data that demonstrate the utility of select AdenoVerse vectors for efficient gene..."/>
GenVec To Present At 2016 Cell & Gene Meeting On The Mesa
Vycor Medical, Inc. reports that a new peer-reviewed study published in "BioMed Research International" shows improvements in visual search following the use of NovaVision's NeuroEyeCoach. The three-centre study was conducted by the School of Psychology of University of Aberdeen, the Neuromotor and Cognitive Rehabilitation Research Centre of University of Verona, and the Department of Psychology of University of Munich."/>
New Clinical Study on NeuroEyeCoach Conclusively Supports Meaningful Improvement in Eye Movement Efficiency
Clovis Oncology, Inc. today announced that data from its rucaparib program in ovarian cancer will be..."/>
Clovis Oncology Announces Rucaparib Data Presentations at ESMO 2016 Congress
ARIAD Pharmaceuticals, Inc. today announced that its partner Otsuka Pharmaceutical Co., Ltd. has received approval from the Japanese Pharmaceuticals and Medical Devices Agency for Iclusig ® for the treatment of chronic myeloid leukemia resistant or intolerant to preceding drug treatment and relapsed or treatment resistant Philadelphia chromosome-positive acute lymphoblastic leukemia."/>
ARIAD Announces Regulatory Approval for Iclusig® (ponatinib) in Japan
Corbus Pharmaceuticals Holdings, Inc., a clinical stage drug development company targeting rare, chronic and serious inflammatory and fibrotic diseases, announced today that Professor Derek Gilroy, Ph.D. presented data on the effects of Resunab in a model of inflammation in healthy volunteers on September 28, 2016. The presentation was made at the 6th European Workshop on Lipid Mediators at Goethe University in Frankfurt am Main, Germany."/>
Corbus Announces Data on Effects of Resunab (JBT-101) in a Clinical Research Model of Resolution of Inflammation
Dermira, Inc., a biopharmaceutical company dedicated to identifying, developing and commercializing innovative, differentiated therapies to improve the lives of patients with dermatologic diseases, today announced that data from its DRM04 Phase 3 clinical program in patients with primary axillary hyperhidrosis will be presented in a late-breaking news session at the 25 th European Academy of Dermatology and Venereology Congress, taking..."/>
Dermira to Present Data from DRM04 Phase 3 Clinical Trials at Late-Breaking News Session at European Academy of Dermatology and Venereology Congress
Karyopharm Therapeutics Inc., a clinical-stage pharmaceutical company, today announced that preclinical and Phase 1 clinical data describing XPO1 inhibition with selinexor, the Company’ s lead, oral Selective Inhibitor of Nuclear..."/>
Karyopharm Publishes Preclinical and Phase 1 Clinical Data for Selinexor in Ovarian Cancer in Clinical Cancer Research Publication
Neogen announced on Tuesday its net income of USD9.89m for the Q1 2017 fiscal year ended 31 August. This marks an increase of 6% from the prior year's first quarter income of USD9, 323,000, or USD0.25 per share. Revenues of USD83.645m were collected for the first quarter of its 2017 fiscal year, a rise of 12% over revenues of USD74.86m in the first quarter of last year."/>
Neogen Corporation posts increase of 6% in net income and 12% in revenues
Quidel Corporation reported on Tuesday the receipt of 510 approval from the US Food and Drug Administration to market its Solana Influenza A+ B assay in the diagnosis of Influenza A and B infections for the upcoming 2016-2017 flu season. The company will market the Solana Influenza A+ B assay for the detection of nucleic acids isolated from nasal and nasopharyngeal swabs from patients with signs and symptoms of respiratory infection to aid in the..."/>
Quidel passes US FDA clearance for launch of Solana Influenza A+B Assay
Proteostasis Therapeutics, Inc., a biopharmaceutical company developing small molecule therapeutics to treat diseases caused by dysfunctional protein processing such as cystic fibrosis, today announced the appointment of Naimish Patel, M.D., C.M., and Elizabeth Tullis, M.D., FRCPC, to its clinical advisory board. Patel is currently a Project Leader in Respiratory, Inflammation and Autoimmunity iMED and Senior Medical Director for AstraZeneca..."/>
Proteostasis Therapeutics Appoints Naimish Patel, M.D., C.M., and Elizabeth Tullis, M.D., FRCPC, to its Clinical Advisory Board
Aerie Pharmaceuticals, Inc., today announced that the Company will host a live webcast of its Investor Day taking place on Wednesday, October 5, 2016 at 12:00p.m. ET in New York, NY. To view the slide presentation and listen to the webcast please visit our website at"/>
Aerie Pharmaceuticals to Host Investor Day on October 5, 2016
Versartis reported on Tuesday that it intends to launch an underwritten public offering of shares of its common stock. The company plans to provide the underwriters with a 30- day option to purchase up to another 15% of the number of shares of common stock sold in connection with the offering. Subject to market conditions, there can be no assurance as to whether or when the offering may be completed, or as to the actual size or terms of the offering."/>
Versartis plans public offering of common shares
Acceleron Pharma stated on Tuesday that Habib Dable has been named as its new president and chief executive officer. Effective 1 December 2016, Dable will succeed current president and CEO John Knopf. Most recently, Dable has served as president of Pharmaceuticals in the US for Bayer AG as well as head of specialty medicine for Bayer HealthCare Pharmaceuticals."/>
Acceleron reports change in executive roles
Foamix Pharmaceuticals revealed on Tuesday that it intends to start a public offering of its ordinary shares. Under the planned public offering, a portion of the ordinary shares will be sold by certain selling shareholders, according to the company. The company plans to provide the underwriters with a 30- day option to purchase up to an additional 15% of the ordinary shares sold in the public offering on the same terms and conditions."/>
Foamix Pharmaceuticals proposes issuance of ordinary shares in follow-on public offering
Xenon Pharmaceuticals announced on Tuesday the addition of Dawn Svoronos to its board of directors. Most recently, Svoronos has served as president of Europe and Canada at Merck& Co, a position she has held until her retirement in 2011.. Prior to president role, Svoronos has worked for 23 years at Merck& Co in senior commercial positions, with a focus on commercial operations and marketing."/>
Xenon Pharmaceuticals elects Dawn Svoronos to board
Array BioPharma said on Tuesday that it has priced a public offering of 18,400,000 shares of its common stock. All of the shares sold in the offering are being sold by the company at a public offering price of USD6.25 per share. Before underwriting discounts and commissions and offering expenses, the company expects gross proceeds from the sale of the shares of approximately USD115m."/>
Array BioPharma prices public offering at USD6.25 per share
Matinas BioPharma Holdings, Inc., a clinical-stage biopharmaceutical company focused on identifying and developing safe and effective broad spectrum therapeutics for the treatment of serious..."/>
Matinas BioPharma Commences Patient Dosing in NIH-Sponsored Phase 2a Study with Lead Anti-Infective Candidate MAT2203
CTD Holdings, Inc., a biotechnology company that develops cyclodextrin-based products for the treatment of disease, today announced that the company made presentations on its US and UK clinical studies at both the 7 th Interactive Workshop on Niemann-Pick Diseases, and the 23 rd Annual Family Conference hosted by Niemann-Pick UK, a non-profit charity in the United Kingdom dedicated to helping families affected by Niemann-Pick Type C disease."/>
CTD Holdings Presents on Clinical Trials at Niemann-Pick UK Conferences
Bavarian Nordic A/S today announced the appointment of Dr. Christopher R. Heery, M.D. to the position of Chief Medical Officer. Heery will oversee preclinical and clinical development of the Company's infectious disease and immuno-oncology portfolio."/>
Bavarian Nordic Appoints Christopher Heery, M.D., as Chief Medical Officer
Assembly Biosciences, Inc., a biotechnology company developing novel oral therapeutics for disorders associated with the human microbiome and the treatment of hepatitis B virus infection, today announced new senior level hires who are primarily focused on advancing the company’ s expanding microbiome platform. The new team members include Miguel Barbosa, PhD, as Chief Scientific Officer of the Microbiome Program; George Grandolfi, PhD, as Vice..."/>
Assembly Biosciences Announces Key Additions to Microbiome Team

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Most Popular Sectors in the News
Sectors Articles in the last 7 days
Information Technology698 Articles
Consumer Discretionary580 Articles
Financials435 Articles
Health Care382 Articles
Industrials380 Articles

Sponsored Financial Commentaries

Request Profile Update

Only a company representative may request an update for the company profile. Documentation will be required.

To contact , please visit . Company data is provided by S&P Global Market Intelligence. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at